Get started

Robotics

Teradyne - Robotics & mobile test equipment buy at $30Teradyne is a mobile test equipment and robotics company, which are both growth CAGR area's over 24% in coming year and coming near full fibonacci retrenchment from June 2017. Current price is $31 and 29.88 was 2017 low, or round $30 entry. Can't see it going below this. TER IRBT NASDAQ:BRKS are a few other robotic stocks on NYSE. About: Teradyne, Inc. supplies automation equipment for test and industrial applications. The Company designs, develops, manufactures and sells automatic test systems used to test semiconductors, wireless products, data storage and complex electronics systems in the consumer electronics, wireless, automotive, industrial, communications, and aerospace and defense industries. Its segments include Semiconductor Test, which includes operations related to the design, manufacturing and marketing of semiconductor test products and services; System Test, which includes operations related to the design, manufacturing and marketing of products and services for defense/aerospace instrumentation test, storage test and circuit-board test; Wireless Test, which includes operations related to the design, manufacturing and marketing of wireless test products and services, and Industrial Automation, which includes operations related to the design, manufacturing and marketing of collaborative robots. Acquired high growth EU robotics company in last 5 years. Div. Yield: 1.1% Mkt Value: 6.0B Bottom of Large cap and room to grow. Ent. Value: 5.2B and another reason hair below $30 expected before resistance. Viewers come to own decisions, this is for own use and comment as you see fit. Most don't, so if you're reading, post a comment or a like. @pokethebear 95% stocks, <5% crypto mining & futures, Sector focus mostly small-mid cap, some large.
TLong
by Pokethebear
EKSO - Buy and hold for future exoskeleton growthI have been wanting to get long-term invested in the stocks that I think will greatly benefit from future technology trends. I believe that pure robotics are further in the future than most people realize, but wearable robotics are much closer to adoption. With that opinion I want to be positioning myself in the exoskeleton market. There are a number of very small exoskeleton companies but the one that stands out me the most is EKSO. A few things that stand out are that they are not only penetrating the medical market but they are also heavily focused on the industrial market, where as the other exoskeleton companies are primarily focused on the medical market. Ekso has also recently landed a few contracts, one with the VA and another with Ford that will help them generate the revenue they need to become profitable. As with most small growth companies the biggest risk here is that they are not yet profitable and will need to generate cash flow through debt or stock dilution, which makes it very important to not jump in too earlier. Up until now it has been too early to buy and hold but I believe with the Ford and VA contracts they may be a few quarters from turning the corner and becoming profitable. Price is still a little rich at this point but I will be looking to buy a little bit around $2.20 - $2.00 as a long term speculative buy-and-hold.
NASDAQ:EKSOLong
by krugman87
Mazor Robotics LTD. Potential bearish divergence.Mazor Robotics reporting solid numbers, looking to announce on 5/9 for last quarter. IGNORING all of that, the chart shows a bearish divergence forming, with two major uptrends. First uptrend since 2016, and second uptrend in place as of 3/21/2017. Price has risen RAPIDLY on second uptrend, while also appearing quite volatile. Checking RSI, we see slight bearish divergence, although nothing to be noticeably worried about if financials stay strong. We are likely to see the chart test the second uptrend before resuming trend upwards. Trend SHOULD continue, but will hit resistance at $69, and $76.00. This will most likely bounce from these levels, and test lows again. If financial reports are positive, expect trend to continue. If price reverses, expect drop down to $56 and $50 respectively. This would make an EXCELLENT buy in point. So watch very closely for reversal patterns, or to see if pattern breaks uptrend. We should expect major resistance at these levels, and a continuation of previous trend upwards. To play the Fibonacci patterns, we would LIKE to see a bounce off the 50% or 61.8% lines, which we would then use as our buy in levels ($50). "For the three months ended September 30th, 2017 vs September 30th, 2016, Mazor Robotics reported revenue of $17.20MM vs $7.63MM (up 125.39%) and basic earnings per share -$0.15 vs -$0.16. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Mazor Robotics reported revenue of $64.95MM vs $36.38MM (up 78.53%) and basic earnings per share -$0.51 vs -$0.84. Mazor Robotics is expected to report earnings on May 9th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.22. The estimated EPS forecast for the next fiscal year is $0.76 and is expected to report on February 13th, 2019." -Yahoo Finance. PLEASE reach out with what you see. This stock is new to me, but I have gotten quite interested as of lately. I do not read into how the news may affect the price for this chart, I just chart trends, patterns, and potential breakouts, based on trends available. Cheers!
MLong
by Shwayze
1
Mad Breakout to $65? Subtle Climb to $60? Quiet Retrace to $53?Oh Novanta. So many possibilities for such a great company. Please forgive the maddening amount of clustered lines. The primary trend line is massive and seemingly unstoppable for a reason. Even though it's gone parabolic, its story is rock solid and almost sexy with everything they have a hand in. As a leader in medical and advanced, industrial markets, Novanta went through a period of optimization several years ago, is currently in organic growth mode and is accelerating its scale from now until 2020 in order to DOUBLE their annual revenue. Oh, and as of their last public statement, they're still on track to do so. Quality products, leadership and personnel (over 375 engineers), coupled with proprietary technologies and over 400 patents, Novanta maintains a stoic and disciplined M&A schedule in order to maintain its edge and continue to innovate by divesting around 9% of revenue in R&D. The crossover between their sectors is astounding. Organic growth, momentum, acquisitions, a great M&A pipeline and leadership positions across key medical and industrial markets are providing, as Matthijs Glastra said, "...a solid foundation for sustainable, profitable growth." If you want a laser, robotics and high level medical play, this is it. Hold Novanta long term. Short term, if you're looking to just trade and not invest, there's been some massive momentum up from the previously, consistent levels held all of April. Based on how the stock has bounced off its bottom trend line, it was a good period of accumulation leading up to another spurt of gains towards the $58+ level. If it should shoot past this and hit what could easily be $65 (based off the previous $15+ jumps) sell immediately, because everyone else obviously did, twice. A retrace back to $53 off this momentum isn't bad and will surely hold or prep for the bounce back up to the $60 range outlined above.
NASDAQ:NOVTLong
by N3utra
Hi-Tech Medical+Robotics Play w/ $10 Stable, Transition RangeWith brand recognition and consistent sales in place, Mazor has stated that 2018 will be a transition year for them, not growth. Therefore, expect the company to aim for stability as it continues to spread its products. Per the last call: "2018 is expected to be a year of transition and our performance is expected to be driven primarily by increased revenues from the expanding installed base. Long-term, we would anticipate the installed base to expand considerably during the length of the global distribution agreement. Over the next five years, the largest result is a cumulative purchase of hundreds of Mazor X systems, which are expected to significantly accelerate procedure volume and growth." Overall trend lines have been followed from 2017 into 2018 in a balanced manner. Some weakness definitely showed up after such a quick run-up into the -now- low part of this year's fib chart. A good period of accumulation presented itself before another push higher in January gave it momentum (along with everything else in the market). February hit, but the stock did not tumble horribly. It had one more push higher that went way beyond what anyone, anywhere was expecting. Forums were happily confused. As such, a LOT of profit taking took place and rightfully so after all the volatility that had been in play. Regardless, the company's fundamentals have not changed and the stock is now back to its previous, stable 2018 levels. This is an excellent range to start a small position, as I expect the stock to continue trading back up close to $70 again with positive market momentum. Anything around the $56 level, where the stock has successfully bounced off of, is great for accumulation. A great company with an excellent product, vision and fundamentals makes holding this for stability within its range (and with opportunities for breakouts with ANY good news) a great pick for 2018. Technical trading within its $10 range ($58-68) is great for those who can time the market. --Additional Backstory-- Mazor is a hi-tech, medical robotics company that specializes in creating systems for assistance during spinal surgery. Everyone knows that surgery is an expensive process and back surgery is extremely costly, difficult and more common than we'd care to imagine. The two systems that Mazor has developed and begun selling (in conjunction with Medtronic) are state of the art and well known within their field. While 2017 was quiet at first, the company began to grow in spurts with a huge push, in part from Medtronic, near the end of the year.
MLong
by N3utra
1
Hair Jump inThe shares of the corporation went up by 22.85% during the previous month. So far this year, the stock had gone up by 8.7%. With these types of results to display analysts, are more optimistic than before! Analyzing the last five market sessions, the stock was able to report 15.47% gains.Clarus Ventures LLC bought a new stake in shares of Restoration Robotics during the fourth quarter.HAIR has been the topic of several other reports and Roth Capital set a $7.50 price objective on shares of Restoration Robotics with a BUY rating in a recent research note.
HShort
by SoWaVvY
1